<a href='https://brc.riken.jp/mus/pcr06536'>Genotyping protocol -PCR-</a> 古関　明彦 FLP/frt system phage P1 loxP sites, yeast FRT (flipase recombination target) site, mouse Uhrf1 genomic DNA true Uhrf1 gene floxed mice. Gene targeting for the Np95 (also known as Uhrf1, ICBP90) allele was done by flanking exons 4 and 5 with Cre-loxP sequences. Conditional deletion of Np95 (exons 4,5) can be achieved by crossing the mice with specific cre deleters such as CreERT2. The Np95 protein is an epigenetic reader and writer molecule, involved in maintenance DNA methylation (Sharif et al., 2007), recognition of H3K9 di/tri methylation (Rothbart et al., 2012) and ubiquitination of histone H3 (Nishiyama et al., 2013). The constitutive null (Np95-KO) mice are embryonically lethal post 9.5 dpc. Ablation of Np95 causes genomewide loss of DNA methylation marks (Sharif et al., 2007). This conditional allele would be useful to study the roles of Np95 in DNA methylation and regulation of other epigenetic modifications such as H3K9 methylation and H3 ubiquitination, by combining with tissue specific Cre deleters C（3〜6か月） Uhrf1遺伝子のfloxedマウス。 理化学研究所統合生命医科学研究センター・古関明彦先生。M1 ES細胞を用いて作出。 NP95 cond ver.2, 6-Uhrf1 floxed NP95 cond ver.2, 6-Uhrf1 floxed Cre/loxP system C (3-6 months) Developed by Haruhiko Koseki, RIKEN Center for Integrative Medical Sciences. M1 ES cell were used to generate the mutant mice. RBRC06536 条件を付加する。<br>利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 Homozygote x Homozygote [or Crossing to C57BL/6JJcl] Homozygote x Homozygote [or Crossing to C57BL/6JJcl] Haruhiko KOSEKI RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. <A HREF="https://mus.brc.riken.jp/ja/mouse_of_month/may_2015_mm" target="_blank">Mouse of the Month May 2015</A> B6.Cg-Uhrf1<tm2.1Hko> B6.Cg-Uhrf1<tm2.1Hko> M1 [(C57BL/6 x 129)F1] Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol>